MedTrace Logo

JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus

NCT05967520 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2023-10-13

No results posted yet for this study

Summary

The trial will evaluate pharmacodynamics，pharmacokinetics，safety，and efficacy of JMKX000189 versus placebo in participants with moderately to severely active systemic lupus erythematosus (SLE) while receiving standard of care (SOC) treatment.

Conditions

  • Lupus Erythematosus, Systemic

Interventions

DRUG

JMKX000189

JMKX000189 will be administered orally once a day

DRUG

Placebo

Placebo will be administered orally once a day

Sponsors & Collaborators

  • Jemincare

    lead INDUSTRY

Principal Investigators

  • Xiaofeng Zeng · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-21
Primary Completion
2025-05-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05967520 on ClinicalTrials.gov